664 related articles for article (PubMed ID: 31163474)
1. [JAK Inhibitors in Rheumatology].
Witte T
Dtsch Med Wochenschr; 2019 Jun; 144(11):748-752. PubMed ID: 31163474
[TBL] [Abstract][Full Text] [Related]
2. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
3. [Inhibition of the Janus kinase-signal transducer and activator of transcription is a new treatment modality of rheumatoid arthritis].
Frøling M; Mikkelsen C; Eggertsen PP; Stern M; van de Looij A; Deleuran B
Ugeskr Laeger; 2017 Oct; 179(44):. PubMed ID: 29084618
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy and safety of tofacitinib and baricitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Bae SC; Lee YH
Z Rheumatol; 2019 Aug; 78(6):559-567. PubMed ID: 30191390
[TBL] [Abstract][Full Text] [Related]
5. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Krüger K
Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of Janus Kinase inhibitor selectivity.
Choy EH
Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
9. Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors.
Atzeni F; Talotta R; Nucera V; Marino F; Gerratana E; Sangari D; Masala IF; Sarzi-Puttini P
Expert Rev Clin Immunol; 2018 Nov; 14(11):945-956. PubMed ID: 30058434
[TBL] [Abstract][Full Text] [Related]
10. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway.
Fitton J; Melville AR; Emery P; Nam JL; Buch MH
Rheumatology (Oxford); 2021 Sep; 60(9):4048-4054. PubMed ID: 33331938
[TBL] [Abstract][Full Text] [Related]
11. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
[TBL] [Abstract][Full Text] [Related]
12. Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis.
Iwata S; Tanaka Y
Expert Rev Clin Immunol; 2016 Oct; 12(10):1047-57. PubMed ID: 27253519
[TBL] [Abstract][Full Text] [Related]
13. JAK-STAT inhibitors for the treatment of immunomediated diseases.
Serra López-Matencio JM; Morell Baladrón A; Castañeda S
Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
[TBL] [Abstract][Full Text] [Related]
14. Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis.
Mogul A; Corsi K; McAuliffe L
Ann Pharmacother; 2019 Sep; 53(9):947-953. PubMed ID: 30907116
[No Abstract] [Full Text] [Related]
15. Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement.
Orsolini G; Bertoldi I; Rossini M
Clin Rheumatol; 2020 Mar; 39(3):727-736. PubMed ID: 31970549
[TBL] [Abstract][Full Text] [Related]
16. Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?
Scott IC; Hider SL; Scott DL
Drug Saf; 2018 Jul; 41(7):645-653. PubMed ID: 29500799
[TBL] [Abstract][Full Text] [Related]
17. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
Kunwar S; Collins CE; Constantinescu F
Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
